Get the Stockscreener App
4.45
3.73%
0.16
After Hours:
4.36
-0.09
-2.02%
Edesa Biotech Inc stock is traded at $4.45, with a volume of 2,627.
It is up +3.73% in the last 24 hours and down -1.11% over the past month.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB01, is a non-steroidal, anti-inflammatory treatment for chronic allergic contact dermatitis. The company operates in a single segment: research and development, manufacturing, and commercialization of innovative pharmaceutical products. The company's EB05 candidate is a monoclonal antibody therapy for hospitalized COVID-19 patients.
See More
Previous Close:
$4.29
Open:
$4.405
24h Volume:
2,627
Relative Volume:
0.41
Market Cap:
$14.30M
Revenue:
-
Net Income/Loss:
$-7.72M
P/E Ratio:
-1.7659
EPS:
-2.52
Net Cash Flow:
$-6.25M
1W Performance:
+0.45%
1M Performance:
-1.11%
6M Performance:
+6.16%
1Y Performance:
+604.11%
1-Day Range:
$4.36
$4.45
1-Week Range:
$4.223
$4.55
52-Week Range:
$0.3913
$8.3331
Edesa Biotech Inc Stock (EDSA) Company Profile
Name
Edesa Biotech Inc
Sector
Industry
Phone
(905) 475-1234
Address
100 SPY COURT, MARKHAM, ON
Edesa Biotech Inc Stock (EDSA) Latest News
Edesa Biotech (NASDAQ:EDSA) Shares Down 1.6% - Defense World
Pardeep Nijhawan Provides Update to Beneficial Ownership of Securities of Edesa Biotech, Inc. - GlobeNewswire Inc.
S&P Smallcap 600 (IQY) QuotePress Release - The Globe and Mail
1 Dividend Stock to Invest in the Domestic Steel Market Now - The Globe and Mail
Celsius Holdings Inc (CELH-Q) QuotePress Release - The Globe and Mail
Mackenzie Investments Announces Results of Special Meetings on Mutual Fund and ETF Mergers - Yahoo Canada Finance
ECB interest rate cut likely as Eurozone economy weaker than expected - Yahoo Finance UK
Veradigm Named as the Top Vendor for End-to-End Revenue Cycle Management Solutions - Yahoo Finance UK
Santander starts $1.7 billion share buyback programme - Yahoo Finance UK
FY2024 Earnings Estimate for Edesa Biotech, Inc. (NASDAQ:EDSA) Issued By HC Wainwright - Defense World
H.C. Wainwright bullish on Edesa Biotech stock amid BARDA study support - Investing.com
Edesa Biotech’s (EDSA) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
500: Something went wrong - Investing.com UK
Edesa Biotech Reports Fiscal 3rd Quarter 2024 Results - GlobeNewswire
Edesa Biotech (NASDAQ:EDSA) Stock Price Down 2% - Defense World
Edesa Biotech Inc expected to post a loss of 58 cents a shareEarnings Preview - XM
Ethiopian Airlines posts 14% jump in full-year revenue - Yahoo Finance UK
Alexis Shamess | Corporate/Commercial Lawyer in Toronto | People - Fasken
Myroslav Chwaluk | Mergers & Acquisitions Lawyer in Toronto | People - Fasken
A. Wojtek BaraniakPolish-speaking Corporate/Commercial lawyer in Toronto | People - Fasken
MoneySmart’s June Lucky Draw 2024 - Yahoo Finance
Ipsen and Foreseen Biotechnology announce exclusive global licensing agreement for antibody-drug conjugate with first-in-class potential - Yahoo Finance UK
Homebuilder Vistry boosts output target as cost inflation softens - Yahoo Finance UK
German environmental authorities approve Tesla site expansion - Yahoo Finance UK
Cipher Pharmaceuticals - The Pharma Letter
Edesa Biotech (NASDAQ:EDSA) Receives Buy Rating from HC Wainwright - Defense World
Allied gaming executive Choi buys shares worth $778k By Investing.com - Investing.com
Bioventus exec sells over $14k in company stock By Investing.com - Investing.com
Edesa's Paridiprubart Selected for U.S.-Funded Platform Trial in General ARDS - Contract Pharma
BARDA Selects Edesa Biotech's Drug for U.S. Funded Platform Trial in General ARDS - StockTitan
Edesa’s Paridiprubart Selected For U.S.-Funded Platform Trial In General ARDS - Contract Pharma
Comparing Assertio (NASDAQ:ASRT) and Edesa Biotech (NASDAQ:EDSA) - Defense World
Short Interest in Edesa Biotech, Inc. (NASDAQ:EDSA) Rises By 32.1% - Defense World
Perritt Capital Management Inc. Has $482000 Stake in Usio, Inc. (NASDAQ:USIO) - Defense World
Anixa Biosciences director buys shares worth over $1,000 By Investing.com - Investing.com
Stephens Inc. AR Has $1.30 Million Stock Holdings in DuPont de Nemours, Inc. (NYSE:DD) - Defense World
French jet engine maker Safran gets Italy's clearance to buy Microtecnica - Yahoo Finance UK
Edesa Biotech Shareholders Approve Board and Compensation PlansTipRanks.com - TipRanks
Edesa Biotech, Inc. Forecasted to Earn FY2024 Earnings of ($1.95) Per Share (NASDAQ:EDSA) - Defense World
FY2024 EPS Estimates for HEICO Co. Lifted by Analyst (NYSE:HEI) - Defense World
EDSA: Preparing IND for Phase 2 Trial of EB06 in Vitiligo - Zacks Small Cap Research
Kiora Pharmaceuticals (KPRX) Stock Forecast and Price Target 2024 - MarketBeat
EDSA Stock Earnings: Edesa Biotech Beats EPS for Q2 2024 - MSN
Edesa Biotech Reports Fiscal 2nd Quarter 2024 Results10.05.2024 - wallstreet:online
Edesa Biotech Reports Fiscal 2nd Quarter 2024 Results | Regional | chronicle-tribune.com - Chronicle-Tribune
EDSA Stock Earnings: Edesa Biotech Beats EPS for Q2 2024 - InvestorPlace
Niagara Energy finalizes $1.36 billion takeover of Enel Peru unit - Yahoo Finance UK
Domain Therapeutics Appoints Sean A. MacDonald as Chief Executive Officer - BioSpace
Edesa Biotech CEO acquires $20k in company shares By Investing.com - Investing.com
Edesa Biotech to Participate in Upcoming Dermatology Meetings - Yahoo Finance
EDSA Stock Quote Price and Forecast - CNN
Edesa Biotech Inc Stock (EDSA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):